TFEB and Alzheimer disease: Multiple TFEB activators have been reported to ameliorate AD-related pathologies function via mTORC1 inhibition, including celastrol [87], chlorogenic acid [88], fisetin [106], flubendazole [107], ouabain [109] and pseudo-ginsenoside-F11 [130].